Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$10.57 USD
+0.45 (4.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $10.53 -0.04 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Inovio Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -135.12 | -279.82 | -303.66 | -167.47 | -120.55 |
Depreciation/Amortization & Depletion | 11.32 | 4.18 | 6.36 | 4.63 | 5.52 |
Net Change from Assets/Liabilities | -10.26 | 19.83 | 50.35 | -71.07 | -3.54 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 9.70 | 39.59 | 31.23 | 55.94 | 20.73 |
Net Cash From Operating Activities | -124.37 | -216.22 | -215.71 | -177.98 | -97.85 |
Property & Equipment | 5.90 | -0.97 | -1.23 | -1.52 | -0.99 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 81.46 | 110.56 | -174.11 | -54.50 | -8.06 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -2.77 | 0.00 |
Net Cash from Investing Activities | 87.36 | 109.59 | -175.34 | -58.80 | -9.04 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.46 | 83.24 | 216.11 | 466.76 | 9.09 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.17 | 94.13 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.47 | -1.40 | -4.61 | -1.65 | 2.18 |
Net Cash from Financing Activities | 5.00 | 81.84 | 211.50 | 465.28 | 105.40 |
Effect of Exchange Rate Changes | 0.00 | -0.03 | -0.03 | 0.03 | 0.00 |
Net Change In Cash & Equivalents | -32.02 | -24.81 | -179.58 | 228.53 | -1.50 |
Cash at Beginning of Period | 46.33 | 71.14 | 250.73 | 22.20 | 23.69 |
Cash at End of Period | 14.31 | 46.33 | 71.14 | 250.73 | 22.20 |
Diluted Net EPS | -6.09 | -14.05 | -17.41 | -12.85 | -14.53 |
Fiscal Year End for Inovio Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -135.12 | -110.11 | -76.18 | -40.65 |
Depreciation/Amortization & Depletion | NA | 11.32 | 12.18 | -0.11 | -0.01 |
Net Change from Assets/Liabilities | NA | -10.26 | -8.15 | -0.77 | 1.48 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 9.70 | 7.99 | 8.08 | 2.51 |
Net Cash From Operating Activities | NA | -124.37 | -98.09 | -68.98 | -36.66 |
Property & Equipment | NA | 5.90 | 5.75 | 5.75 | 5.77 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 81.46 | 61.66 | 67.16 | 13.23 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 87.36 | 67.41 | 72.91 | 19.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 5.46 | 3.62 | 2.92 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.47 | -0.47 | -0.46 | -0.42 |
Net Cash from Financing Activities | NA | 5.00 | 3.16 | 2.46 | -0.42 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -32.02 | -27.52 | 6.38 | -18.09 |
Cash at Beginning of Period | NA | 46.33 | 46.33 | 46.33 | 46.33 |
Cash at End of Period | NA | 14.31 | 18.80 | 52.71 | 28.24 |
Diluted Net EPS | NA | -1.05 | -1.56 | -1.56 | -1.92 |